Doggrell Sheila A
Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand.
Expert Opin Pharmacother. 2003 Dec;4(12):2363-6. doi: 10.1517/14656566.4.12.2363.
Preterm delivery is the major determinant of infant mortality and there is a lack of treatments for this condition. Women presenting for prenatal care with a history of a spontaneous preterm delivery were assigned 17 alpha-progesterone caproate (17P) 250 mg/week i.m. between 16 and 20 weeks of gestation or placebo until 36 weeks of gestation or delivery, whichever came first. The primary outcome was preterm delivery before 37 weeks of gestation and this occurred less often in the 17P group than in the placebo group (36.3 versus 54.9%, respectively; p < 0.001). Among the infants, there was a reduction in the risk of a birth weight of < 2500 g in the 17P compared to the placebo group (27.2 versus 41%, respectively). As a result of this clinical trial, 17P should be routinely used as a preventative in women with a history of spontaneous preterm delivery.
早产是婴儿死亡的主要决定因素，且针对这种情况缺乏治疗方法。有自发性早产史且前来接受产前护理的女性，在妊娠16至20周期间被分配接受每周一次肌肉注射250毫克己酸17α-孕酮（17P），或接受安慰剂治疗，直至妊娠36周或分娩，以先到者为准。主要结局是妊娠37周前早产，17P组发生早产的情况比安慰剂组少（分别为36.3%和54.9%；p<0.001）。在婴儿中，与安慰剂组相比，17P组出生体重<2500克的风险降低（分别为27.2%和41%）。基于这项临床试验的结果，17P应常规用作有自发性早产史女性的预防用药。
